Tirzepatide
Safety and Efficacy of NA-931 and Tirzepatide in Adults Who Are Overweight or Obese
Eli Lilly · Phase 2 · Not yet recruiting · Enrollment 224
| Arm | Population | Dose | Weeks | Estimand | Weight change |
|---|---|---|---|---|---|
| Placebo Comparator: Placebo | Obesity or overweight | n/r | 4 | n/r | n/r |
| Placebo + Tirzepatide 5 mg | Obesity or overweight | 5 mg | 4 | n/r | n/r |
| Placebo + Tirzepatide 10 mg | Obesity or overweight | 10 mg | 4 | n/r | n/r |
| NA-931 60mg to NA-931 150 mg + no Tirzepatide | Obesity or overweight | 150 mg | 4 | n/r | n/r |
| NA-931 60 mg + Tirzepatide 5 mg | Obesity or overweight | 5 mg | 4 | n/r | n/r |
| NA-931 120 mg + Tirzepatide 5 mg | Obesity or overweight | 5 mg | 4 | n/r | n/r |
| NA-931 150 mg + no Tirzepatide | Obesity or overweight | 150 mg | 4 | n/r | n/r |
| NA-931 150 mg + Tirzepatide 2.5 mg | Obesity or overweight | 2.5 mg | 4 | n/r | n/r |
| NA-931 150 mg + Tirzepatide 5 mg | Obesity or overweight | 5 mg | 4 | n/r | n/r |